SNSE Insider Trading
Insider Ownership Percentage: 23.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Sensei Biotherapeutics Share Price & Price History
Current Price: $10.56
Price Change: ▲ Price Increase of +1.86 (21.38%)
As of 12/4/2025 05:00 PM ET
Sensei Biotherapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/11/2023 | John Celebi | CEO | Buy | 25 | $17.00 | $425.00 | 5,565 |  |
| 6/1/2023 | Apeiron Investment Group Ltd. | Major Shareholder | Sell | 172,083 | $31.60 | $5,437,822.80 | | |
| 2/23/2023 | Apeiron Investment Group Ltd. | Major Shareholder | Buy | 110 | $32.20 | $3,542.00 | 124,296 | |
Sensei Biotherapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/13/2025 | XTX Topco Ltd | 62,903 | $31K | 0.0% | +351.7% | 0.250% |  |
| 2/13/2025 | Renaissance Technologies LLC | 156,800 | $77K | 0.0% | -27.3% | 0.623% | |
| 11/15/2024 | National Bank of Canada FI | 45,575 | $27K | 0.0% | +355.8% | 0.181% | |
| 11/14/2023 | Newtyn Management LLC | 1,800,000 | $1.35M | 0.3% | -1.5% | 7.200% | |
| 11/14/2022 | RA Capital Management L.P. | 683,529 | $1.06M | 0.0% | -5.5% | 2.225% | |
| 7/22/2022 | Truist Financial Corp | 19,934 | $45K | 0.0% | -60.5% | 0.065% | |
| 5/3/2022 | Leo Brokerage LLC | 14,845 | $34K | 0.0% | N/A | 0.048% | |
| 11/16/2021 | Millennium Management LLC | 258,659 | $2.72M | 0.0% | N/A | 0.846% | |
| 11/16/2021 | Moore Capital Management LP | 49,341 | $0.52M | 0.0% | -61.3% | 0.161% | |
| 11/12/2021 | Tao Capital Management LP | 32,784 | $0.35M | 0.1% | N/A | 0.107% | |
| 11/12/2021 | The Manufacturers Life Insurance Company | 13,478 | $0.14M | 0.0% | N/A | 0.044% | |
| 11/12/2021 | Geode Capital Management LLC | 273,978 | $2.88M | 0.0% | +93.2% | 0.896% | |
| 11/10/2021 | Citigroup Inc. | 2,409 | $25K | 0.0% | +565.5% | 0.008% | |
| 11/9/2021 | BlackRock Inc. | 1,000,322 | $10.52M | 0.0% | +175.2% | 3.270% | |
| 11/5/2021 | Truist Financial Corp | 70,374 | $0.74M | 0.0% | N/A | 0.230% | |
| 11/4/2021 | Deutsche Bank AG | 12,021 | $0.13M | 0.0% | +158.3% | 0.039% | |
| 11/1/2021 | SG Americas Securities LLC | 12,614 | $0.13M | 0.0% | N/A | 0.041% | |
Data available starting January 2016
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Read More on Sensei Biotherapeutics
Today's Range
Now: $10.56
52 Week Range
Now: $10.56
Volume
128,727 shs
Average Volume
24,179 shs
Market Capitalization
$13.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.32
